Navigation Links
Revalesio Presents Update on the Development of RNS60 As A Therapeutic for Acute Heart Disease At the American Heart Association Scientific Sessions
Date:11/18/2013

TACOMA, Wash., Nov. 18, 2013 /PRNewswire/ -- Revalesio presented an update on the cellular protective effects of RNS60 in a pig model of acute myocardial infarction (AMI, heart attacks) at the 2013 American Heart Association Scientific Sessions in Dallas, Texas. As reported earlier this year at the American College of Cardiology meeting in San Francisco, RNS60 provided a 30% reduction in infarct size compared to normal saline in a model of AMI, the leading cause of death in the developed world. Despite many years of research and investigational studies, no drug has been developed to protect or limit the damage to the heart muscle caused by heart attacks. RNS60 was administered by intra-coronary injection and peripheral intravenous infusion. In this update, Revalesio researchers looked at intracellular pathways involved in cell death and survival and found that RNS60 treatment significantly modulates the level of a protein called HSP90, one of the general stress response proteins found in all cell types.

"After the initial observation of the significant improvement in infarct size achieved by RNS60 treatment, we are now diving deep into the mechanism of action behind this effect," said Revalesio's Andreas Kalmes, Ph.D., who presented the data. "The data presented at this meeting show that RNS60 inhibits apoptosis, or programmed cell death, in heart muscle cells, and provides an important clue that RNS60 affects the general stress response of cells. Apoptosis has been recognized as an important driver in heart muscle damage following a heart attack, and as a promising target to improve outcome for patients. These findings further validate our approach to develop RNS60 as a therapeutic for heart attack patients."

The reduction in infarct size, suppression of programmed cell death as a consequence of a heart attack, and the excellent safety profile provides strong rationale for the development of RNS60 as a novel treatment option for patients with AMI.

About RNS60
Revalesio has pioneered the use of RNS60 as a therapeutic that alters whole cell conductance through effects on voltage-gated ion channels and other voltage-sensing proteins, thereby modulating the activity of G protein-coupled receptors and the secretion of cytokines resulting in decreased inflammation and cell death. RNS60 contains CSN that are created by subjecting normal saline to Taylor-Couette-Poiseuille (TCP) flow. RNS60 has demonstrated a reduction in inflammatory responses that are linked to numerous diseases, including neurodegenerative, respiratory and cardiovascular diseases.

About Revalesio Corporation
Revalesio is a pioneering clinical stage biotechnology company dedicated to restoring hope and transforming lives. Founded in 2000 and based in Tacoma, Washington, Revalesio has partnered with leaders in biomedical research around the world to develop RNS60. Revalesio has an extensive patent portfolio on a novel class of anti-inflammatory products and is advancing the use of CSN in neuroinflammatory, respiratory, cardiovascular and other inflammatory diseases. For more information about Revalesio, visit revalesio.com.

Press Contact:
Jesse Thomas
253-926-5567
Email

Read more news from Revalesio Corporation


'/>"/>
SOURCE Revalesio
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Revalesio Initiates Phase IIa Study of RNS60 in Multiple Sclerosis at University Hospital Zurich
2. Revalesio Presents Data Showing RNS60 Alters Disease Progression in Animal Model of Alzheimers Disease Through the PI3k-Akt Pathway
3. Pi2 Solutions Presents on Pharmacovigilance Literature Screening at Major European Risk Management Meeting
4. Regulus Presents Positive Preclinical Data Demonstrating that microRNA-21 Plays an Important Role in Alport Syndrome
5. Panacea Pharmaceuticals Presents Three Papers Regarding Its Nanoparticle-Based Therapeutic Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting at National Harbor, MD
6. Rheumatology Network Presents Latest Advances Against Baffling Inflammatory Diseases From Major Rheumatology Conference
7. Sangamo BioSciences Presents Clinical Data From SB-728-T HIV Study Demonstrating Long-Term Immune Reconstitution and Reduction in the HIV DNA Reservoir In Subjects with Long-Term Infection
8. Sangamo BioSciences Presents Clinical Data From HIV Study Demonstrating Sustained Control Of Viremia
9. Healthcare Trust of America CEO Scott D. Peters Presents at the Arizona State University Real Estate Council
10. Biocartis Presents the Successful use of Idylla[TM] for the Detection of the BRAF Mutation Status in Tumour Samples at the International AACR Congress (American Association for Cancer Research) in Boston
11. 3-V Biosciences Presents Positive Data for Novel FASN Inhibitor at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2019)... , ... September 17, 2019 , ... Drs. Nickelice Brand ... implant placement and restorations in one office. Dental implants are a nearly permanent, ... loss. , Dental implants have a high success rate when placed by highly trained ...
(Date:9/17/2019)... ... September 17, 2019 , ... Summer is a time for barbecues, parties and picnics ... our teeth and gums. Dr. Douglas Ng, family dentist in San Luis Obispo ... time for ice cream, and popsicles and ice-filled cold drinks to go along with the ...
(Date:9/14/2019)... CULVER CITY, Calif. (PRWEB) , ... ... ... recent World Molecular Imaging Society (WMIS) annual congress in Montreal provided a ... the studies highlighted presentations on Artificial Intelligence (AI) to detect breast cancer, ...
Breaking Medicine Technology:
(Date:9/17/2019)... ... September 17, 2019 , ... Six Consulting Inc. (SIX) ... of canines – specifically golden retrievers - through innovative cancer prevention medicine. A ... – one out of five retrievers in the United States will die from ...
(Date:9/17/2019)... ... September 17, 2019 , ... Caravan Health is ... in the country, the company announced today. High-performing community health systems and providers ... increase cost efficiency. This opportunity is open to those new to value-based Medicare ...
(Date:9/17/2019)... Calif. (PRWEB) , ... September 17, 2019 , ... ... , CA, recently announced that he has been certified by the American Academy ... dentistry is used to correct a wide range of orofacial conditions such as ...
(Date:9/17/2019)... ... September 17, 2019 , ... The Center for Information ... of the third edition of The Gift of Participation. Written by CISCRP Founder, ... families to navigate the clinical research process. The new edition offers a fresh ...
(Date:9/14/2019)... ... September 13, 2019 , ... ... showcased several first-in-human studies on the detection and treatment of infectious diseases ... of these ground-breaking studies were noninvasive detection of residual HIV infected cell ...
Breaking Medicine News(10 mins):